Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$19 Mln
Revenue (TTM)
$14 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5.6
Industry P/E
24.51
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.4
Face value
--
Shares outstanding
1,722,409
CFO
$-82.73 Mln
EBITDA
$-97.96 Mln
Net Profit
$-101.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Evoke Pharma (EVOK)
| 148.9 | 2.9 | 112.4 | 139.7 | -21.6 | -51.0 | -31.5 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Evoke Pharma (EVOK)
| 402.3 | -64.6 | -60.8 | -78.7 | 59.3 | -34.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Evoke Pharma (EVOK)
|
11.0 | 19.0 | 14.4 | -5.2 | -7.6 | -113.6 | -- | 5.6 |
| 12.5 | 3,981.1 | 3,018.8 | 72.1 | 12.6 | -80 | 56.7 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,120.8 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.2 | 2.8 | |
| 23.1 | 11,474.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat... symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California. As of December 15, 2025, Evoke Pharma, Inc. operates as a subsidiary of QOL Medical, LLC. Read more
Co-Founder, President, CEO, COO, Secretary, Treasurer & Director
Mr. Matthew J. D'Onofrio MBA
Co-Founder, President, CEO, COO, Secretary, Treasurer & Director
Mr. Matthew J. D'Onofrio MBA
Headquarters
Solana Beach, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Evoke Pharma Inc (EVOK) is $11.00 (NASDAQ) as of 17-Dec-2025 09:30 EDT. Evoke Pharma Inc (EVOK) has given a return of -21.57% in the last 3 years.
Since, TTM earnings of Evoke Pharma Inc (EVOK) is negative, P/E ratio is not available.
The P/B ratio of Evoke Pharma Inc (EVOK) is 5.64 times as on 02-Mar-2026, a 0 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.23
|
0.93
|
|
2023
|
-0.45
|
-1.36
|
|
2022
|
-0.09
|
0.18
|
|
2021
|
-0.01
|
0.04
|
|
2020
|
-0.04
|
-0.15
|
The 52-week high and low of Evoke Pharma Inc (EVOK) are Rs 32.50 and Rs 1.94 as of 05-Apr-2026.
Evoke Pharma Inc (EVOK) has a market capitalisation of $ 19 Mln as on 02-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Evoke Pharma Inc (EVOK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.